Eudrali

EUROPEAN MEDICINES AGENCY

Sudralink

SCIENCE MEDICINES HEALTH

Tracking

New Package

Drafts

Address

Options

Logout

COVID-19.mRNA.Vaccine.BioNTech -Subject: CHMP Interim Opinion and CHMP Overview Agnese.Auzina-Vundere@ema.europa.eu From: gudenus@granzer.biz To: vanessa.seguin@ema.europa.eu covid-19.mrna.vaccine.biontech-CC: 5735@ema.europa.eu agnese.auzina-vundere@ema.europa.eu Mon, 30 Nov 2020 17:39:20 +0100 Sent: Expiration: Mon, 28 Dec 2020 17:39:20 +0100

Message:

Dear Rosmarie,

Please find attached CHMP Interim Opinion together with the CHMP Overview and LoQ as adopted today, 30th of November 2020 for COVID-19.mRNA.Vaccine.BioNTech-5735 focusing on the assessment of quality data.

Should you require any clarification on the above, please do not hesitate to contact your PL:vanessa.seguin@ema.europa.eu Kind regards,

Agnese

Procedure Assistant

Filename	Type	Size
COVID-19 mRNA Vaccine BioNTech - CHMP Overview and LoQ.docx	MS Word Document	836kb
COVID-19 mRNA Vaccine BioNTech - CHMP Opinion.docx	MS Word Document	113kb
	Vaccine BioNTech - CHMP Overview and LoQ.docx COVID-19 mRNA Vaccine BioNTech -	Vaccine BioNTech - CHMP Overview and LoQ.docx COVID-19 mRNA MS Word Document Vaccine BioNTech -

Package retrieved by

